Literature DB >> 34508572

The Relationship Between Endoscopic and Clinical Recurrence in Postoperative Crohn's Disease: A Systematic Review and Meta-analysis.

Alessandro Ble1, Cecilia Renzulli1, Fabio Cenci1, Maria Grimaldi1, Michelangelo Barone1, Rocio Sedano2,3, Joshua Chang2, Tran M Nguyen2, Malcolm Hogan2, Guangyong Zou2,4, John K MacDonald2, Christopher Ma2,5, William J Sandborn2,6, Brian G Feagan2,3,4, Emilio Merlo Pich1, Vipul Jairath2,3,4.   

Abstract

BACKGROUND AND AIMS: We aimed to quantify the magnitude of the association between endoscopic recurrence and clinical recurrence [symptom relapse] in patients with postoperative Crohn's disease.
METHODS: Databases were searched to October 2, 2020, for randomised controlled trials [RCTs] and cohort studies of adult patients with Crohn's disease with ileocolonic resection and anastomosis. Summary effect estimates for the association between clinical recurrence and endoscopic recurrence were quantified by risk ratios [RR] and 95% confidence intervals [95% CI]. Mixed-effects meta-regression evaluated the role of confounders. Spearman correlation coefficients were calculated to assess the relationship between these outcomes as endpoints in RCTs. An exploratory mixed-effects meta-regression model with the logit of the rate of clinical recurrence as the outcome and the rate of endoscopic recurrence as a predictor was also evaluated.
RESULTS: In all, 37 studies [N = 4053] were included. For eight RCTs with available data, the RR for clinical recurrence for patients who experienced endoscopic recurrence was 10.77 [95% CI 4.08 to 28.40; GRADE moderate certainty evidence]; the corresponding estimate from 11 cohort studies was 21.33 [95% CI 9.55 to 47.66; GRADE low certainty evidence]. A single cohort study showed a linear relationship between Rutgeerts score and clinical recurrence risk. There was a strong correlation between endoscopic recurrence and clinical recurrence treatment effect estimates as trial outcomes [weighted Spearman correlation coefficient 0.51].
CONCLUSIONS: The associations between endoscopic recurrence and subsequent clinical recurrence lend support to the choice of endoscopic recurrence to monitor postoperative disease activity and as a primary endpoint in clinical trials of postoperative Crohn's disease.
© The Author(s) 2021. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Postoperative Crohn’s disease; clinical recurrence; endoscopic recurrence

Mesh:

Year:  2022        PMID: 34508572      PMCID: PMC8919832          DOI: 10.1093/ecco-jcc/jjab163

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   10.020


  52 in total

Review 1.  Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies.

Authors:  Alexandra D Frolkis; Jonathan Dykeman; María E Negrón; Jennifer Debruyn; Nathalie Jette; Kirsten M Fiest; Talia Frolkis; Herman W Barkema; Kevin P Rioux; Remo Panaccione; Subrata Ghosh; Samuel Wiebe; Gilaad G Kaplan
Journal:  Gastroenterology       Date:  2013-07-27       Impact factor: 22.682

Review 2.  American Gastroenterological Association Institute Guideline on the Management of Crohn's Disease After Surgical Resection.

Authors:  Geoffrey C Nguyen; Edward V Loftus; Ikuo Hirano; Yngve Falck-Ytter; Siddharth Singh; Shahnaz Sultan
Journal:  Gastroenterology       Date:  2016-11-10       Impact factor: 22.682

3.  American Gastroenterological Association Institute Technical Review on the Management of Crohn's Disease After Surgical Resection.

Authors:  Miguel Regueiro; Fernando Velayos; Julia B Greer; Christina Bougatsos; Roger Chou; Shahnaz Sultan; Siddharth Singh
Journal:  Gastroenterology       Date:  2016-11-10       Impact factor: 22.682

4.  GRADE guidelines: 9. Rating up the quality of evidence.

Authors:  Gordon H Guyatt; Andrew D Oxman; Shahnaz Sultan; Paul Glasziou; Elie A Akl; Pablo Alonso-Coello; David Atkins; Regina Kunz; Jan Brozek; Victor Montori; Roman Jaeschke; David Rind; Philipp Dahm; Joerg Meerpohl; Gunn Vist; Elise Berliner; Susan Norris; Yngve Falck-Ytter; M Hassan Murad; Holger J Schünemann
Journal:  J Clin Epidemiol       Date:  2011-07-30       Impact factor: 6.437

5.  Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial.

Authors:  Edoardo Savarino; Giorgia Bodini; Pietro Dulbecco; Lorenzo Assandri; Linda Bruzzone; Fabrizio Mazza; Anna Chiara Frigo; Valentina Fazio; Elisa Marabotto; Vincenzo Savarino
Journal:  Am J Gastroenterol       Date:  2013-09-10       Impact factor: 10.864

6.  Rates of Postoperative Recurrence of Crohn's Disease and Effects of Immunosuppressive and Biologic Therapies.

Authors:  Pauline Rivière; Séverine Vermeire; Marie Irles-Depe; Gert Van Assche; Paul Rutgeerts; Quentin Denost; Albert Wolthuis; Andre D'Hoore; David Laharie; Marc Ferrante
Journal:  Clin Gastroenterol Hepatol       Date:  2020-04-06       Impact factor: 11.382

7.  Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection.

Authors:  Miguel Regueiro; Brian G Feagan; Bin Zou; Jewel Johanns; Marion A Blank; Marc Chevrier; Scott Plevy; John Popp; Freddy J Cornillie; Milan Lukas; Silvio Danese; Paolo Gionchetti; Stephen B Hanauer; Walter Reinisch; William J Sandborn; Dario Sorrentino; Paul Rutgeerts
Journal:  Gastroenterology       Date:  2016-03-03       Impact factor: 22.682

8.  Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study.

Authors:  Alessandro Armuzzi; Carla Felice; Alfredo Papa; Manuela Marzo; Daniela Pugliese; Gianluca Andrisani; Francesco Federico; Italo De Vitis; Gian Lodovico Rapaccini; Luisa Guidi
Journal:  J Crohns Colitis       Date:  2013-06-27       Impact factor: 9.071

9.  Prevention of postoperative recurrence of Crohn's disease: Tripterygium wilfordii polyglycoside versus mesalazine.

Authors:  Jianan Ren; Xiuwen Wu; Nansheng Liao; Gefei Wang; Chaogang Fan; Song Liu; Huajian Ren; Yunzhao Zhao; Jieshou Li
Journal:  J Int Med Res       Date:  2013-01-24       Impact factor: 1.671

10.  Adalimumab vs Azathioprine in the Prevention of Postoperative Crohn's Disease Recurrence. A GETECCU Randomised Trial.

Authors:  Antonio López-Sanromán; Isabel Vera-Mendoza; Eugeni Domènech; Carlos Taxonera; Vicente Vega Ruiz; Ignacio Marín-Jiménez; Jordi Guardiola; Luisa Castro; María Esteve; Eva Iglesias; Daniel Ceballos; Pilar Martínez-Montiel; Javier P Gisbert; Miguel Mínguez; Ana Echarri; Xavier Calvet; Jesús Barrio; Joaquín Hinojosa; María Dolores Martín-Arranz; Lucía Márquez-Mosquera; Fernando Bermejo; Jordi Rimola; Vicente Pons; Pilar Nos
Journal:  J Crohns Colitis       Date:  2017-10-27       Impact factor: 9.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.